Full-Time

Senior Medical Science Liaison

Telix Pharmaceuticals

Telix Pharmaceuticals

501-1,000 employees

Develops targeted radiation therapies for cancer

No salary listed

Brisbane QLD, Australia

In Person

Category
🩺Medical, Clinical & Veterinary (1)
Required Skills
Market Research
Requirements
  • Undergraduate degree with a focus on sciences, healthcare, or medical sciences required
  • Graduate degree preferred (e.g. PharmD, PhD, MD, RN)
  • Certification by the Medical Radiation Practice Board of Australia (MRPBA) preferred
  • 5+ years’ experience as a Medical Science Liaison or in medical affairs
  • Thorough understanding of relevant policies guiding the Pharmaceutical Industry
  • Experience/expertise in interpretation of scientific data, market research, and competitive intelligence tools
Responsibilities
  • Identify and forge professional peer-to-peer relationships with National, Regional, and Local key opinion leaders
  • Aid in new site onboarding, helping the site optimize PET camera settings and protocols to increase proper use of Telix radiopharmaceuticals in commercial settings and clinical trial setup
  • Align and execute field activities in support of the Medical Affairs Strategic plan, including congress strategy, pre and post launch activities, and clinical trial recruitment
  • Identify and communicate research gaps, opportunities, and relevant field intelligence to inform medical strategy
  • Accelerate recruitment efforts and enhance subject retention at targeted clinical trial sites
  • Leverage expertise to enhance and broaden knowledge among internal and external stakeholders
  • Attend medical/scientific meetings to represent Medical Affairs with KOLs and other HCPs, strengthen individual expertise/proficiency as well as capture, integrate, and summarize information of strategic interest
  • Appropriately facilitate submission of Medical Education grants and Investigator-Initiated Research
  • Provide product training and presentations to internal and external stakeholders to ensure accurate communication and utilization of Telix products. Support in deck creation and material review
  • Support cross-functional colleagues (e.g. commercial, marketing, clinical operations), in appropriate activities
  • Actively participate in relevant team meetings, organizational activities, and HQ-driven medical affairs and clinical research activities (e.g. advisory boards, publication planning, investigator meetings)
  • Leveraging unique skill sets, assume lead responsibility for project work identified by Medical Affairs leadership and/or organizational priorities
  • Maintain a high level of team knowledge of and appropriately implement current local pharmaceutical regulation and ensure implementation of Telix policies and procedures. Ensure all MSL activities, including external interactions, are conducted in accordance with Telix objectives, compliance policies and procedures as well as with legal and ethical standards.
Desired Qualifications
  • Experience in GU oncology, radiopharmaceuticals preferred
  • Experience in a role covering several countries is an advantage
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells biopharmaceutical products aimed at improving the diagnosis and treatment of cancer and rare diseases. The company focuses on creating therapeutic and diagnostic solutions that use targeted radiation, which helps healthcare providers make better treatment decisions and offers personalized therapy for patients with significant medical needs. Their product pipeline includes treatments for urologic cancers like prostate and kidney cancer, neuro-oncology conditions such as glioma, musculoskeletal cancers like sarcoma, and bone marrow conditioning. Telix operates a global supply chain to manufacture and distribute its products, generating revenue through sales to healthcare institutions. The company emphasizes sustainability, patient care, and ethical practices, aiming to create lasting value for patients, shareholders, and employees.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Telix's Illuccix PSMA-PET imaging agent approved in Germany and France enhances market presence.
  • The rise of personalized medicine aligns with Telix's focus on targeted radiation therapy.
  • Global radiopharmaceutical market growth to $10.6 billion by 2026 benefits Telix's offerings.

What critics are saying

  • Illuccix faces competition from other PSMA-PET imaging agents in Germany and France.
  • Gozellix launch in the U.S. may struggle against existing prostate cancer imaging agents.
  • TLX101 glioma therapy's promising results may not ensure successful commercialization.

What makes Telix Pharmaceuticals unique

  • Telix specializes in molecularly-targeted radiation therapy for cancer and rare diseases.
  • The company focuses on urologic, neuro-oncology, and musculoskeletal oncology therapeutic areas.
  • Telix integrates sustainability and ethical practices into its operations and patient care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

2%
Medical Device Network
Jun 23rd, 2025
Telix launches new PET radiochemistry solution

Telix launches new PET radiochemistry solution.

Telix Pharmaceuticals
Jun 20th, 2025
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

Telix theranostic programs and satellite symposia on Innovation in PSMA and CAIX imaging featured at SNMMI 2025.

PharmaTutor
Jun 11th, 2025
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S.

Telix launches new prostate cancer imaging agent, Gozellix, in U.S.

PR Newswire
Jun 5th, 2025
Telix'S Illuccix® Psma-Pet Imaging Agent Approved In Germany

MELBOURNE, Australia, June 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enhances the options available to healthcare providers across Germany for PSMA-PET[3] imaging and will ensure more patients can access this essential diagnostic tool. Illuccix, after radiolabelling with gallium-68, is indicated in Germany for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk PCa prior to primary curative therapy. Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy

Telix Pharmaceuticals
Apr 28th, 2025
Telix's Illuccix PSMA-PET Imaging Agent Approved in France

Telix will partner with IRE ELiT S.A. (the radiopharmaceutical subsidiary of IRE Group), a leading provider of radioisotopes and radiopharmaceuticals for nuclear medicine, for the marketing and promotion of Illuccix(R) to healthcare professionals in France.